FDA asks for post-marketing studies for Foundayo: what changed and what to track

What happened (plain English)

According to a Reuters report, the FDA is requiring post-marketing studies for Eli Lilly’s newly approved obesity pill Foundayo, and the agency is also seeking additional data related to liver injury.

“Post-marketing” means after approval. The medication can be on the market while more data is collected to better understand safety, real-world use, and outcomes.

What “post-marketing studies” usually mean for patients

• More monitoring and data collection over time (sometimes via registries, claims data, or targeted studies).
• More attention to specific risks that regulators want clarified.
• More paperwork (prior auth, appeals, coverage changes) as plans react to new information.

None of this automatically tells you what you should do personally. It does suggest one thing clearly: keeping your information organized makes appointments and follow-ups easier.

A practical tracking checklist (high leverage)

If you’re taking (or considering) Foundayo, here are non-medical items you can track so you’re not rebuilding your story from memory each visit:

• Medication timeline: start date, pauses, dose changes, and why (as you understood it).
• Symptoms journal: date/time, what you noticed, severity (1–10), and what else might have changed (sleep, diet, other meds).
• Labs and results: what was ordered, when, and the actual values (with a photo/PDF if you have it).
• Appointments: upcoming visits, what you want to ask, and what was decided.
• Insurance/admin: prior auth dates, call reference numbers, letters, receipts.

Questions you can bring to your next appointment

• “Is there anything specific you want me to track between visits?”
• “What labs (if any) do you typically monitor, and how often?”
• “If I notice a new symptom, what details are most useful for you to know?”

Source

Reuters (2026-04-14): https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-requires-lilly-conduct-post-marketing-studies-obesity-pill-2026-04-14/

Reminder: This page is educational only. It does not provide medical advice or instructions. If you have urgent symptoms, seek appropriate medical care.